Wound dressing with adhesive margin

Information

  • Patent Grant
  • 11141318
  • Patent Number
    11,141,318
  • Date Filed
    Tuesday, July 25, 2017
    6 years ago
  • Date Issued
    Tuesday, October 12, 2021
    2 years ago
Abstract
A wound dressing comprising: a backing sheet; a layer of pressure-sensitive adhesive on the backing sheet; an island of absorbent material having smaller area than the backing sheet and applied onto a central region of the backing sheet so as to leave a margin of adhesive-coated backing sheet around the absorbent material, and an apertured wound facing layer applied over the absorbent material and adhered to the backing sheet around said island by said pressure-sensitive adhesive, wherein the apertured wound facing layer comprises an apertured substrate having a coating of a silicone gel on the wound facing surface thereof, the open area of the apertured wound facing layer is from about 5% to about 75%, and the apertured wound facing layer comprises apertures having an open area of from about 2 mm2 to about 100 mm2.
Description

The present invention relates to island-type wound dressings.


Island-type wound dressings comprise an absorbent region and an adhesive backing sheet covering the absorbent region and extending beyond the edges of the absorbent region to provide an adhesive margin around the absorbent region for attachment of the dressing to intact skin around the wound to be treated. The adhesive margin provides secure attachment of the dressing without the need for secondary dressings such as a bandage. The adhesive margin also reduces or prevents leakage of wound exudate from the edges of the dressing.


The adhesive used in such dressings is typically a medically acceptable pressure-sensitive adhesive (PSA) such as an acrylic-based PSA. Such adhesives provide a strong bond to skin, but as a result they are not readily repositionable, and they may cause skin irritation and/or discomfort when the dressing is removed. Moreover, the PSA is not normally permeable to oxygen or water vapour and therefore interferes with normal skin transpiration.


It is known to provide a discontinuous, e.g. patterned, layer of the PSA in order to address the above problems. However, application of a patterned layer of PSA increases the complexity of the manufacturing process and increases the risk of liquid leakage through the PSA to the edges of the dressing.


In a first aspect, the present invention provides a wound dressing comprising: a backing sheet, a layer of pressure-sensitive adhesive on the backing sheet; an island of absorbent material having smaller area than the backing sheet and applied onto a central region of the backing sheet so as to leave a margin of adhesive-coated backing sheet around the absorbent material, and an apertured wound lacing layer applied over the absorbent material and adhered to the backing sheet around said island by said pressure-sensitive adhesive, wherein the apertured wound facing layer comprises an apertured substrate having a coating of a silicone elastomer on the wound facing surface thereof, the open area of the apertured wound facing layer is from about 5% to about 75%, and the aperture wound facing layer-comprises apertures having an open area of from about 2 mm2 to about 100 mm2.


The adhesive-coated backing sheet may have any shape, such as square, rectangular, circular, oval, trapezium-shaped, suitably with rounded corners.


The adhesive-trolled hacking sheet supports the absorbent island and suitably provides a barrier to passage of microorganisms through the dressing. Suitably, the adhesive-coated backing sheet is substantially liquid-impermeable. The adhesive-coated backing sheet is suitably semipermeable. That is to say, the adhesive-coated backing sheet is suitably permeable to water vapour, but not permeable to liquid water or wound exudate. Suitably, the adhesive-coated backing sheet is also microorganism-impermeable. Suitable continuous conformable adhesive-coated backing sheets will suitably have a moisture vapor transmission rate (MVTR) of the backing sheet alone of 300 to 30000 g/m2/24 hrs, suitably 1000 to 1500 g/m2/24 hrs, and in one embodiment 1000 to 5000 g/m2/24 hrs, at 37.5° C. at 100% to 10% relative humidity difference. The adhesive-coated backing sheet thickness is suitably in the range of 10 to 1000 micrometers, more suitably 100 to 500 micrometers.


Suitable polymers for forming the adhesive-coated backing sheet include polyurethanes and poly alkoxyalkyl acrylates and methacrylates such as those disclosed in GB-A-1280631. Suitably, the adhesive-coated backing sheet comprises a continuous layer of a high density blocked polyurethane foam that is predominantly closed-cell. A suitable adhesive-coated backing sheet material is the polyurethane film available under the Registered Trade Mark ESTANE 5714F. Also suitable are elastomeric polymeric esters such as Du Pont HYTREL (Registered Trade Mark).


The absorbent island may comprise any of the layers conventionally used for absorbing wound fluids, serum or blood in the wound healing art, including gauzes, nonwoven fabrics, superabsorbents, hydrogels and mixtures thereof. Suitably, the absorbent island comprises a layer of hydrophilic polyurethane foam on a wound facing side thereof, such as an open celled hydrophilic polyurethane foam prepared in accordance with EP-A-0541391. The absorbent island may further comprise a wicking layer. This may be a layer of a nonwoven fibrous web, for example a carded web of viscose staple fibers. The basis weight of the absorbent layer may suitably be in the range of 50-500 g/m2, such as 100-400 g/m2. The uncompressed thickness of the absorbent layer may be in the range of from 0.5 mm to 10 mm, such as 1 mm to 4 mm. The free (uncompressed) liquid absorbency measured for physiological saline may suitably be in the range of 5 to 30 g/g at 25° C.


The area of the absorbent island is suitably in the range of from 1 cm2 to 400 cm2, more suitably from 4 cm2 to 200 cm2, still more suitably from about 10 cm2 to about 150 cm2, for example from about 16 cm2 to about 100 cm2. Dressings of the latter size are especially suitable for the treatment of leg ulcers.


The island has a smaller area than the adhesive-coated backing sheet such that an adhesive-coated margin of the backing sheet extends around the island. Normally, the adhesive-coated margin extends around every edge of the absorbent island. Suitably, the adhesive-coated margin has a mean width of from 0.5 to 5 cm, suitably from 1 to 3 cm. The adhesive-coated margin may be made up of an inner margin covered by the apertured coated layer, and an outer margin extending outside the apertured coated layer, as explained further below.


The pressure-sensitive adhesive layer is suitably pressure-sensitive adhesive layer of the type conventionally used for island-type wound dressings. The PSA layer is suitably a continuous layer, but it may be apertured or interrupted in some embodiments. Acrylic-based pressure sensitive adhesive are suitable. In embodiments, a pressure sensitive adhesive based on acrylate ester copolymers, polyvinyl ethyl ether and polyurethane as described for example in GB-A-1280631. The basis weight of the PSA layer is suitably 20 to 250 g/m2, and more suitably 50 to 150 g/m2.


The apertured layer having a coating of silicone elastomer provides a weakly adherent (tacky) or non-adherent wound facing layer over the absorbent layer. In addition, the apertured layer having a coating of silicone elastomer extends over at least part of the adhesive-coated margin. In this part of the margin, the apertured layer covers a portion of the PSA-coated surface of the backing sheet but allows adhesion of the pressure-sensitive adhesive through the apertures of the layer resulting in reduced overall adherency of the backlog sheet in this part of the margin. The overlap of the apertured coated layer and the adhesive-coated backing sheet around the absorbent layer also serves to attach the apertured coated layer to the backing sheet thereby securing the laminate. The silicone elastomer coating is suitably hydrophobic, whereby leakage of wound fluid through the edges of the dressing is inhibited. The silicone elastomer coating may be tacky or non-tacky.


The apertures in the apertured layer are suitably large enough to allow skin contact of the backing layer PSA through the apertures when the dressing is applied to skin around a wound. Suitably, the said apertures have an open area of from about 4 mm2 to about 50 mm2, for example from about 5 mm2 to about 30 mm2. This refers to the average (mean) area of the apertures. Suitably, at least about 90% of the apertures in the apertured layer have open area in the specified ranges. Suitably, at least about 90%, for example substantially all, of the apertures have substantially the same size and shape. Suitably, said apertures consist essentially of a regular array of apertures. The apertures may be of any shape, but suitably they are circular, oval or polygonal. Suitably, the open area of the apertured layer is from about 10% to about 70% of the total area, for example from about 20% to about 50% of the total area, for example about 25% to about 40% of the total area. Suitably, the density of the apertures is from about 1000 to about 100,000 apertures per m2, for example about 5000 to about 50,000 apertures per m2.


Likewise, in order to ensure sufficient adherency of the PSA through the apertures of the apertured layer, the apertured layer is suitably thin. In embodiments, the thickness of the apertured wound facing layer is less than about 1 mm, for example from about 0.02 mm to about 0.5 mm, in embodiments from about 0.05 mm to about 0.2 mm. The term “thickness” in this context refers to the combined thickness of the silicone coating and substrate.


The apertured substrate may be any medically acceptable apertured sheet material, including textile materials such as gauzes. Suitably, the apertured substrate is a unitary substrate such as a unitary polymer mesh or an apertured polymer film. Suitable polymer materials include polyethylene, polypropylene, polyester, polyvinyl acetate, and ethylene vinyl acetate. Suitably, the film substrate has a thickness of from about 1 μm to about 100 μm, for example from about 5 μm to about 25 μm. In other embodiment the substrate is a woven or nonwoven textile material, typically having an uncompressed thickness of from about 0.1 mm to about 1 mm.


In embodiments, the apertured wound facing layer is smaller than the adhesive-coated backing sheet, whereby an adhesive-coated margin of the backing sheet extends around the apertured wound facing layer. This continuous PSA margin provides additional security of attachment and leak resistance around the edges of the dressing. However, it can be made narrower than the PSA-coated margin of conventional island dressings because of the adherency of the inner margin covered by the apertured layer. Thus, in embodiments, the margin of PSA-coated backing sheet around the absorbent island that is covered by the apertured layer has a mean width of from about 5 mm to about 30 mm, for example from about 10 mm to about 20 mm. The outer margin of PSA-coated backing sheet only (where present) has a mean width of from about 2 mm to about 20 mm, for example from about 5 mm to about 15 mm, typically about 10 mm.


In embodiments, the apertured wound facing material comprises lines or weakness substantially parallel to, and spaced from, one or more edges of the apertured wound facing material. These lines of weakness define tear-off strips along one or more edges of the apertured wound facing material that allow the size of the apertured wound facing material (and hence the width of the PSA-coated margin around the outside of the apertured wound facing material) to be varied according to the clinical requirements. Thus, for a heavily-exuding wound, a wider PSA-coated margin around the edges of the dressing may be desirable. On the other hand, for lightly exuding wounds, or where easy repositioning of the dressing is desirable, little or no PSA-coated margin around the outside of the apertured wound facing material may be preferable. Thus, in some embodiments the apertured wound facing sheet may be coterminous with the PSA-coated backing sheet prior to removal of any of the tear strips so that there is no continuously PSA-coated margin around the apertured wound facing sheet until removal of the tear strips.


The lines of weakness may, for example comprise lines of perforations or score lines. Suitably, one or more lines of weakness defining tear-off strips are defined in all edges of the apertured wound facing material so as to allow uniform increasing of the PSA-coated margin. Suitably, the width of the tear-off strips (i.e. the average spacing of the lines of weakness from the edges of the apertured sheet is from about 5 mm to about 20 mm, for example about 8 mm to about 15 mm. Suitably, a pull tab is attached to, or formed integrally with, each tear strip defined by the lines of weakness to assist removal of the tear strip. Suitably, a release coating such as a silicone or a fluoropolymer coating may be provided on the underside of the tear-off strips of the apertured wound contacting layer to assist removal of the strips.


The silicone coating on the wound facing side of the apertured layer is suitably a hydrophobic, tacky or non-tacky silicone polymer. The silicone elastomer coating is suitably coated only on the wound facing side of the apertured layer.


The total coating weight of the silicone is suitably from about 15 g/m2 to about 500 g/m2, for example from about 40 g/m2 to about 250 g/m2, typically from about 50 g/m2 to about 150 g/m2. The silicone is suitably a soft skin adhesive silicone composition. Suitable chemistry is described below. The silicone is suitably hydrophobic.


Suitably, the silicone composition is a so-called soft skin adhesive silicone elastomer. Such silicones can be made by an addition reaction (hydrosilylation) between (a) a vinyl functional polydimethyl siloxane, such as bis-dimethyl vinyl polydimethylsiloxane (PDMS), and (b) a hydrogen functional siloxane, such as dimethyl, methylhydrogen siloxane copolymers, hydrogen dimethylsiloxy terminated PDMS. The cure reaction is catalyzed by a hydrosilylation catalyst, such as a noble metal catalyst, suitably a platinum catalyst. A silicone prepolymer composition may further comprise a polymerization inhibitor that is evaporated from said composition during said step of thermally partially curing, for example 2-methyl-3-butyn-2-ol. Where present, the polymerization inhibitor is suitably present in an amount of from about 0.001 wt. % to about 1 wt %, for example from about 0.01 wt % to about 0.1 wt. % before curing. Alternatively, no polymerisation inhibitor is present in the silicone compositions.


Silicone skin adhesive compositions are suitably supplied as two-part systems: Part A contains at least the vinyl prepolymer and the catalyst, while Part B contains the vinyl prepolymer and the SiH siloxane cross linker. The components are mixed immediately before use, optionally with addition of a polymerization inhibitor.


In embodiments, the silicone coating composition comprises or consists essentially of the following components:


(A) a diorganopolysiloxane having at least 2 alkenyl groups in each molecule;


(B) an organohydrogenpolysiloxane having at least 2 silicon-bonded hydrogen atoms in each molecule, in a quantity sufficient for the ratio between the number of moles of silicon-bonded hydrogen atoms in this component and the number of moles of alkenyl groups in component (A) to have a value of from about 0.6:1 to about 20:1.


(C) optionally a platinum group metal catalyst suitably in a quantity providing 0.1 to 500 weight parts as platinum group metal per 1,000,000 weight parts component (A); and


(D) optionally, a volatile polymerization inhibitor, suitably selected from: alkyne alcohols such as 2-methyl-3-butyn-2-ol, 3,5-dimethyl-1-hexyn-3-ol, and phenylbutynol; ene-yne compounds such as 3-methyl-3-penten-1-yne and 3,5-dimethyl-3-hexen-1-yne; tetramethyhyltrahexenyl-cyclotetrasiloxane; and benzotriazole.


The diorganopolysiloxane, component (A), used in the instant invention is the base component of the total composition. This diorganopolysiloxane must contain at least 2 alkenyl groups in each molecule in order for this composition to cure into a rubbery elastic silicone rubber coating composition.


The diorganopolysiloxane (A) comprises essentially straight-chain organopolysiloxane with the average unit formula RnSiO(4−n)/2, wherein R is selected from substituted and unsubstituted monovalent hydrocarbon groups and n has a value of 1.9 to 2.1 R may be exemplified by alkyl groups such as methyl, ethyl, propyl, and others; alkenyl groups such as vinyl, allyl, and others; aryl groups such as phyenyl, and others; and haloalkyl groups such as 3,3,3-trifluoropropyl and others. The diorganopolysiloxane (A) should have a viscosity at 25° C. of at least 100 centipoise (1 d Pa·s). When such factors as the strength of the silicone rubber coating membrane, and blendability are taken into account, the viscosity of diorganopolysiloxane (A) at 25° C. is preferably from 1,000 centipoise (1 Pa·s) to 100,000 centipoise (100 Pa·s). The diorganopolysiloxane (A) may be exemplified by dimethylvinylsiloxy-endblocked dimethylpolysiloxanes, dimethylvinylsiloxy-endblocked dimethylsiloxane-methylvinylsiloxane copolymers, and dimethylvinyl-siloxy-endblocked dimethylsiloxane-methylphenylsiloxane copolymers.


Component (B), an organopolysiloxane that contains at least 2 silicon-bonded hydrogen atoms in each molecule, is a crosslinker for the composition of the instant invention. The organopolysiloxane (B) may be exemplified by trimethylsiloxy-endblocked methylhydrogenpolysiloxanes, trimethylsiloxy-endblocked dimethylsiloxanemethylhydrogensiloxane copolymers, dimethylphenylsiloxy-endblocked methylphenylisloxanemethylhydrogensiloxane copolymers, cyclic methylhydrogenpolysiloxanes, and copolymers that contain the dimethylhydrogensiloxy unit and SiO4/2 unit. The organohydrogenpolysiloxane (B) should be added in a quantity that the ratio between the number of moles of silicon-bonded hydrogen atoms in this organohydrogenpolysiloxane and the number of moles of alkenyl groups in component (A) has a value of 0.6:1 to 20:1.


The platinum group metal catalyst, component (C), used in the compositions is a curing catalyst. The platinum group metal catalyst (C) may be exemplified by platinum micropowder, platinum black, chloroplatinic acid, platinum tetrachloride, olefin complexes of chloroplatinic acid, alcohol solutions of chloroplatinic acid, complexes between chloroplatinic acid and alkenylsiloxanes, rhodium compounds, and palladium compounds. The platinum group metal catalyst (C) should be added generally at 0.1 to 500 weight parts as platinum group metal per 1,000,000 weight parts component (A), and is preferably used at 1 to 50 weight parts as platinum group metal per 1,000,000 weight parts component (A). The reaction will not develop adequately at less than 0.1 weight parts, while additions in excess of 500 weight parts are uneconomical.


The coated substrate is then subjected to thermal curing to at least partially cure the silicone. The thermal curing is suitably performed continuously by passing the coated substrate through an oven. Suitable thermal curing conditions include exposure to a temperature of from about 80° C. to about 200° C., for example about 120° C. to about 180° C. for a time of from about 1 minute to about 10 minutes, for example about 1.5 minutes to about 5 minutes. The elevated temperature results in evaporation of any polymerization inhibitor from the silicone composition and therefore promotes polymerization of the silicone. The resulting material is chemically polymerized, but may be capable of further curing by ionizing radiation for example during sterilization.


The adhesive dressing according to the present invention may further comprise at least one removable cover sheet to cover the absorbent island and the adhesive-coated margin(s) around the absorbent island. The cover sheet covers and protects the absorbent island and prevents premature adhesion of the adhesive layer. The cover sheet is removed by the care giver immediately before application of the dressing.


The cover sheet may comprise a film of polyethylene, polypropylene or fluorocarbons and papers coated with these materials. Suitably, the cover sheet is a release-coated paper sheet, such as a silicone, release-coated paper sheet. Examples of silicone-coated release papers are POLYSLIK (Registered Trade Mark) supplied by H.P. Smith & Co., offered in various formulations to control the degree of adhesion of the paper to the adhesive surface.


Suitably, the dressing comprises a first removable cover sheet having a first edge and a second removable cover sheet that meets the first cover sheet along the first edge.


Certain suitable dressings have a central cover sheet with first and second opposed edges, and two side cover sheets that meet the central cover sheet along the opposed edges. Suitably, the opposed edges are substantially parallel. This arrangement of three cover sheets is especially suitable for positioning of relatively large dressings, such as sacral dressings, as described in detail in EP-A-0117632.


Suitably, along each of said edges where the cover sheets meet, one of the cover sheets is folded back to provide a folded-back margin, and the other cover sheet overlaps the said folded-back margin. This provides art easy-to-grasp margin on each cover sheet in the region of overlap to assist removal of the cover sheets by the care giver.


In the case of the embodiment comprising three cover sheets described above, each side cover sheet is suitably folded back along each of said edges where the cover sheets meet to provide a folded-back margin, and the central cover sheet overlaps the said folded-back margin, suitably as described in EP-A-0117632.


Suitably the dressing according to the present invention is sterile and packaged in a microorganism-impermeable container.


The dressing of the invention may be made by conventional cutting and lamination of the various layers. The apertured coated top sheet may be made by coating a suitable film substrate with a fluid silicone precursor mixture as described above, followed by thermal curing as described above. The coating may be done by any conventional means, such as by roller, doctor blade, spraying or dipping. In embodiments, the fluid silicone precursor may be coated onto an already-apertured substrate, in which case the coated substrate is suitably passed over an air blower to blow excess precursor out of the apertures as described for example in WO-A-9319709.


In other embodiments, the film substrate may be apertured, for example by die cutting, for example after the coating and curing steps. In a particularly suitably embodiment, the die cutting is performed after curing of a layer of the silicone sandwiched between the support film and a release sheet.


Accordingly, in a further aspect the present invention provides a method of making a wound dressing as described herein comprising the steps of forming a precursor laminate comprising a layer of silicone sandwiched between a polymeric film support sheet and a release sheet; die cutting aperture perimeters through the polymeric film support sheet and the silicone layer; and removing the release sheet to leave an apertured wound facing layer comprising an apertured polymeric film having a coating of a silicone gel on the wound facing surface thereof.


In a further aspect the present invention provides a method of making a wound dressing as described herein comprising the steps of: forming a precursor laminate comprising a layer of a fluid silicone prepolymer sandwiched between a polymeric film support sheet and a release sheet; curing said fluid silicone prepolymer; die cutting aperture perimeters through the polymeric film support sheet and the silicone layer; and removing the release sheet to leave an apertured wound facing layer comprising an apertured polymeric film having a coating of a silicone gel on the wound facing surface thereof.


In a further aspect the present invention provides a method of making a wound dressing as described herein comprising the steps of: forming a precursor laminate comprising a layer of silicone sandwiched between a polymeric film support sheet and a release sheet, wherein said precursor laminate is formed by disposing a layer of a fluid silicone prepolymer on said release sheet, curing said fluid silicone prepolymer, and disposing said polymeric film support sheet on the silicone layer; die cutting aperture perimeters through the polymeric film support sheet and rite silicone layer; and removing the release sheet to leave an aperatured wound facing layer comprising an apertured polymeric film having a coating of a silicone gel on the wound facing surface thereof.


Suitably, the method according to the present invention further comprises one or more of the following steps: coating one surface of a backing sheet with a layer of pressure sensitive adhesive; applying an island of absorbent material to a central region of the adhesive-coated surface of the backing sheet, wherein the absorbent material has a smaller area than the backing sheet so as to leave an adhesive-coated margin of the backing sheet around the island; and applying said apertured wound facing layer over said island with said polymeric film support sheet facing the backing sheet, wherein a margin of said wound contacting laminate is adhered to said adhesive-coated margin around said island.


Suitably, the method further comprises the step of packaging the dressing in a microorganism-impermeable container, and sterilizing the dressing. Sterilization may be, and preferably is, effected using an ethylene oxide (EtO) sterilization process, which is known in the art for sterilization of medical and pharmaceutical products that cannot support conventional high temperature steam sterilization in a typical process, gaseous EtO is mixed with air at a ratio of at least 3% EtO and infiltrates the dressing to kill any micro-organisms remaining from the production process. Most EtO sterilization processes involve a pre-conditioning stage, a sterilization stage and a degassing stage.


Sterilization may also be effected with ionizing radiation, such as gamma radiation Commercially available gamma irradiation equipment includes equipment often used for gamma irradiation sterilization of products for medical applications. Cobalt 60 sources are appropriate. Total absorbed doses are suitably from 20 to 60 kGy, more suitably from about 35 to 50 kGy and dose rates are suitably about 7 to 8 kGy/hour. It has been (bund that the ionizing radiation provides a further benefit of further curing the silicone elastomer.


The methods of the invention may be used to make any products according to the invention. Any feature disclosed herein in relation to any one or more aspects of the invention is suitable for use in any of the other aspects defined herein.





Embodiments of the present invention will now be described by way of example with reference to the accompanying drawings, in which:



FIG. 1 shows a longitudinal cross-section through a dressing according to the invention;



FIG. 2 shows a perspective view of the apertured top sheet of the dressing of FIG. 1;



FIG. 3 shows a bottom perspective view of a dressing according to FIG. 1, partially cut away to show detail;



FIG. 4 shows a bottom perspective view of a dressing according to FIG. 1 further comprising a cover sheet;



FIG. 5 shows the dressing of FIG. 3 enclosed in a microorganism-impermeable pouch;



FIG. 6 shows a perspective view of an apertured top sheet incorporating tear strips;



FIG. 7 shows a bottom perspective view of a dressing according to a second embodiment of the present invention, incorporating the apertured top sheet of FIG. 6, and



FIG. 8 shows a schematic view of a method according to the invention of making the silicone-coated apertured top sheet.





Referring to FIGS. 1 to 4, the wound dressing 1 according to the invention comprises a conventional backing sheet 2 of microporous, semipermeable polyurethane. The backing sheet 2 is coated on its wound-facing surface with a continuous layer 4 of medically acceptable acrylic pressure-sensitive adhesive. An absorbent island is located in the central region of the wound-facing surface of the backing sheet 2 so as to leave an adhesive-coated margin of the backing sheet 2 around the island. The absorbent island is made up of nonwoven textile absorbent/wicking layer 6 and a polyurethane foam wound facing layer 8. Each of these layers is 1-2 mm thick in the dry uncompressed state, i.e. before use. The absorbent/wicking layer 6 is formed of viscose fibers optionally mixed with gel-forming fibers or other superabsorbents. The polyurethane foam layer is formed of a hydrophilic polyurethane foam available from Systagenix Wound Management Ltd. under the Registered Trade mark TIELLE. It is produced as described in EP-A-0541391.


The dressing 1 further comprises an apertured wound-facing top sheet 10 that covers the absorbent island and extends around the edges of the absorbent island so that it adheres to the margins of the adhesive-coated backing sheet around the absorbent island. The top sheet 10 is smaller than the backing sheet 2, whereby a relatively narrow adhesive-coated margin 12 of the backing sheet extends around all edges of the top sheet 10.


The top sheet 10 is formed from an apertured film substrate 14 coated on its wound facing surface with a laser of silicone elastomer 16. The film substrate is formed of polyurethane, has thickness about 10 μm. The circular apertures of diameter 6 mm are arranged in a regular array at 10,000 apertures per m2 such that the open area of the film substrate is about 28%. The thickness/coating weight of the silicone is about 50 g/m2. The resulting overall thickness of the top sheet is about 80 μm. The relatively large aperture size and low thickness of the top sheet 10 enable pressure-sensitive adhesive from the laser 4 to penetrate through the apertures and adhere to skin located below the top sheet 10. The degree of adherency can be controlled by varying the tackiness of the silicone elastomer, the size of the apertures, and the overall open area of the top sheet, thereby allowing optimization of adherency for leak prevention and secure attachment versus ease of removal and repositionability. In this embodiment, the additional narrow adhesive margin 16 around the top sheet is provided for further leak prevention from the dressing. In other embodiments, the top sheet may be conterminous with the backing sheet so that there is no narrow adhesive margin 16.


Referring to FIG. 3, release-coated cover sheets 20,22 are positioned over the wound facing side of the dressing. Inside edges 24,26 of the cover sheets 20,22 are folded over to provide for easy removal of the cover sheets before application of the dressing.


Referring to FIG. 4, the wound dressing of FIG. 3 is shown sterile and packaged in a microorganism-impermeable envelope 30 having a transparent window 32.


Referring to FIG. 5, this embodiment 40 of the apertured wound facing sheet consists of an apertured polymer film substrate layer 42 and silicone coating layer 44 as described above in relation to the first embodiment. Lines of perforations 45,46,47,48 are formed in the film substrate laser 42 parallel to the four edges of the wound facing sheet, to define respective tear stops along each edge. Respective pull tabs 51,52,53,54 are formed integrally with the film substrate layer for removal of the tear strips. A release coating of non-adherent silicone or fluoropolymer may be provided on the surface of the tear strips, opposite the silicone-coated wound facing surface to assist removal of the tear strips in use, as described below.


Referring to FIG. 6, the wound dressing 60 according to this embodiment comprises a PSA coated backing sheet 62, and absorbent island 64, and release-coated cover sheets 65,66 as described above in relation to the first embodiment. The apertured wound facing sheet 40 as shown in FIG. 5 completely covers the backing sheet 62. The dressing may be used in this configuration by removing the cover sheets 65,66 and applying the dressing around a wound. The PSA-coated margin of the backing sheet 62 is completely covered by the apertured wound facing sheet, whereby the overall adherence of the margin is reduced to allow easy removal and/or repositioning of the dressing. For wounds requiring stronger adherency, the tear strips on the apertured wound facing layer may be removed by pulling on the tabs 50,51,52,53 to expose a margin of the PSA coated backing sheet extending around the apertured wound facing sheet.


Referring to FIG. 8, the steps in the preparation of the apertured wound facing sheet according to this embodiment start from a release sheet 80 of a polymeric film material. This is coated with a layer 82 of the fluid silicone precursor composition as described below. The coating may be done by any conventional means such as spraying, roller and/or doctor blade. A layer 84 of the substrate film material is then laminated over the fluid silicone layer. The laminate is then heated to thermally cure the silicone elastomer by passing through an oven held at 150° C. Typical conditions are 5 passes at 4.2 m/min, total residence time 1.5 minutes. This results in thermal partial cure of the silicone coating. The material is then allowed to cool. The resulting cured laminate passes through a die cutter that makes circular cuts 86 through the substrate film material 84 and the cured silicone layer 88, but not through the release sheet 80. The release sheet 80 is then peeled from the silicone layer to separate the apertured coated substrate 90 from the release sheet 80. The silicone and support film from the apertures adheres to the release sheet and is removed with the release sheet 80. The silicone coating composition is prepared by mixing Components A and B of a soft silicone skin adhesive silicone elastomer kit supplied by Dow Corning under product reference Q7-9177. The components are mixed in weight ratio 50:50. Component A comprises a bis-dimethylvinyl terminated polydimethylsiloxane and a platinum catalyst. Component B composes a bis-hydride terminated polydimethylsiloxane. To the mixture is added 2-methyl-3-butyn-2-ol inhibitor at a concentration of 0.02 wt %.


Alternatively, and again with reference to FIG. 8, the release sheet 80 of a polymeric film material is coated with a layer 82 of the fluid silicone precursor composition by any conventional means such as spraying, roller and/or doctor blade and the coated film is then heated to thermally cure the silicone elastomer by passing through an oven held at 150° C. Typical conditions are 1 pass at 0.8 m/min, total residence time 1.5 minutes. This results in thermal cure of the silicone coating. Layer 84 of the substrate film material is then laminated over the silicone layer. The material is then allowed to cool. The resulting cured laminate passes through a die cutter that makes circular cuts 86 through the substrate film material 84 and the cured silicone layer 88, but not through the release sheet 80. The release sheet 80 is then peeled from the silicone layer to separate the apertured coated substrate 90 from the release sheet 80. The silicone and support film from the apertures adheres to the release sheet and is removed with the release sheet 80. The silicone coating composition is prepared by mixing Components A and B of a soft silicone skin adhesive silicone elastomer kit supplied by Dow Corning under product reference Q7-9177. The components are mixed in weight ratio 50:50. Component A comprises a bis-dimethylvinyl terminated polydimethylsiloxane and a platinum catalyst. Component B comprises a bis-hydride terminated polydimethylsiloxane.


The above embodiments have been described by way of example only. It is understood that many other embodiments falling within the scope of the accompanying claims will be apparent to the skilled reader. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Claims
  • 1. A wound dressing comprising: a backing sheet;an island of absorbent material on a central region of the backing sheet;a pressure-sensitive adhesive disposed between the backing sheet and the island and coupling the island to the backing sheet, and on at least a portion of the backing sheet around the island; andan apertured layer having at least two apertures and a wound-facing side coated with a silicone elastomer;wherein the apertured layer is adhered to the backing sheet by the pressure-sensitive adhesive and is configured to allow a portion of the pressure-sensitive adhesive through the apertures to contact skin of a user when the wound dressing is applied to the user; andwherein the apertured layer comprises lines of weakness substantially parallel to, and spaced from, one or more edges of the apertured layer defining a tear-off strip or strips along one or more edges of the apertured layer.
  • 2. The wound dressing according to claim 1, wherein the apertured layer comprises apertures positioned substantially in a uniform array.
  • 3. The wound dressing according to claim 1, wherein a thickness of the apertured layer is less than 1 mm.
  • 4. The wound dressing according to claim 1, wherein the apertured layer further comprises an apertured substrate.
  • 5. The wound dressing according to claim 4, wherein the silicone elastomer is coated on a first side of the apertured substrate.
  • 6. The wound dressing according to claim 4, wherein the apertured substrate is an apertured film.
  • 7. The wound dressing according to claim 1, further comprising: a margin of the pressure-sensitive adhesive around the island of absorbent material;wherein the island of absorbent material is positioned between the backing sheet and the apertured layer.
  • 8. The wound dressing according to claim 7, wherein the island of absorbent material comprises an absorbent layer and a polyurethane foam layer.
  • 9. The wound dressing according to claim 8, wherein the absorbent layer comprises a nonwoven textile formed of viscose fibers mixed with gel-forming fibers.
  • 10. The wound dressing according to claim 8, wherein the polyurethane foam layer comprises a hydrophilic polyurethane foam.
  • 11. The wound dressing according to claim 7, wherein the margin of the pressure-sensitive adhesive extends around the apertured layer to form an adhesive-coated border.
  • 12. The wound dressing according to claim 11, wherein a portion of the margin of the pressure-sensitive adhesive covered by the apertured layer has a mean width of from 5 mm to 30 mm, and the adhesive-coated border has a mean width of from 2 mm to 20 mm.
  • 13. The wound dressing according to claim 1, wherein a pull tab is attached to, or formed integrally with, each of the tear-off strip or strips to assist removal of the tear-off strip or strips.
  • 14. The wound dressing according to claim 1, wherein the silicone elastomer is a hydrophobic silicone polymer.
  • 15. The wound dressing according to claim 1, wherein the apertured layer comprises an open area of from 5% to 75% of a total area of the apertured layer.
  • 16. The wound dressing according to claim 1, wherein the apertured layer comprises apertures having an open area of from 2 mm2 to 100 mm2.
  • 17. The wound dressing according to claim 15, wherein the apertured layer comprises apertures of which at least about 90% have an open area of from 5 mm2 to 50 mm2.
  • 18. A wound dressing comprising an apertured layer comprising an apertured polymeric film support layer and a coating of silicone elastomer disposed on a first surface of the apertured polymeric film support layer, and wherein the apertured layer comprises a line or lines of weakness substantially parallel to, and spaced from, one or more edges of the apertured layer defining a tear-off strip or strips along one or more edges of the apertured layer, wherein the tear-off strip or strips comprise a release coating on a second surface of the aperture layer opposite the first surface of the aperture layer, wherein the apertured layer comprises apertures having an open area of from 2 mm2 to 100 mm2.
  • 19. The wound dressing of claim 18, wherein the apertured layer further comprises apertures positioned substantially in a uniform array.
  • 20. The wound dressing of claim 18, wherein a thickness of the apertured layer is less than about 1 mm.
  • 21. The wound dressing of claim 18, wherein a thickness of the apertured layer is between 0.02 mm and 0.5 mm.
  • 22. The wound dressing of claim 18, further comprising: a backing sheet;a layer of pressure-sensitive adhesive disposed on at least a portion of the backing sheet; andan island of absorbent material having a smaller area than the backing sheet;wherein the backing sheet comprises a margin of the pressure-sensitive adhesive around the island of absorbent material;wherein the island of absorbent material is positioned between the backing sheet and the apertured layer.
  • 23. The wound dressing of claim 22, wherein the island of absorbent material comprises an absorbent layer and a polyurethane foam layer.
  • 24. The wound dressing of claim 23, wherein the absorbent layer comprises a nonwoven textile formed of viscose fibers mixed with gel-forming fibers.
  • 25. The wound dressing of claim 23, wherein the polyurethane foam layer comprises a hydrophilic polyurethane foam.
  • 26. The wound dressing according to claim 18, wherein a pull tab is attached to, or formed integrally with, each of the tear-off strip or strips to assist removal of the tear-off strip or strips.
  • 27. The wound dressing according to claim 18, wherein an open area of the apertured layer is from 5% to 75% of a total area of the apertured layer.
Priority Claims (1)
Number Date Country Kind
1222770 Dec 2012 GB national
Parent Case Info

This application is a continuation of U.S. Non-Provisional patent application Ser. No. 14/653,760 filed on Jun. 18, 2015, entitled “Wound Dressing with Adhesive Margin,” which claims the priority benefit of PCT Application No. PCT/1132013/060862, filed on Dec. 12, 2013, which claims the priority benefit of GB 1222770.8, filed on Dec. 18, 2012, all of which are incorporated herein by reference for all purposes.

US Referenced Citations (321)
Number Name Date Kind
1355846 Rannells Oct 1920 A
1944834 Bennett, Jr. Jan 1934 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2910763 Lauterbach Nov 1959 A
2969057 Simmons Jan 1961 A
3066672 Crosby, Jr. et al. Dec 1962 A
3172808 Baumann et al. Mar 1965 A
3367332 Groves Feb 1968 A
3376868 Mondiadis Apr 1968 A
3520300 Flower, Jr. Jul 1970 A
3568675 Harvey Mar 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3742952 Magers et al. Jul 1973 A
3774611 Tussey et al. Nov 1973 A
3777016 Gilbert Dec 1973 A
3779243 Tussey et al. Dec 1973 A
3826254 Mellor Jul 1974 A
3852823 Jones Dec 1974 A
3967624 Milnamow Jul 1976 A
3983297 Ono et al. Sep 1976 A
4080970 Miller Mar 1978 A
4096853 Weigand Jun 1978 A
4139004 Gonzalez, Jr. Feb 1979 A
4141361 Snyder Feb 1979 A
4163822 Walter Aug 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4256109 Nichols Mar 1981 A
4261363 Russo Apr 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4297995 Golub Nov 1981 A
4333468 Geist Jun 1982 A
4360015 Mayer Nov 1982 A
4373519 Errede et al. Feb 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4414970 Berry Nov 1983 A
4419097 Rowland Dec 1983 A
4465485 Kashmer et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4525374 Vaillancourt Jun 1985 A
4529402 Weilbacher et al. Jul 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4569348 Hasslinger Feb 1986 A
4600001 Gilman Jul 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielsen Aug 1986 A
4640688 Hauser Feb 1987 A
4655754 Richmond et al. Apr 1987 A
4664652 Weilbacher May 1987 A
4664662 Webster May 1987 A
4710165 McNeil et al. Dec 1987 A
4715857 Juhasz et al. Dec 1987 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4753230 Carus et al. Jun 1988 A
4758220 Sundblom et al. Jul 1988 A
4787888 Fox Nov 1988 A
4826494 Richmond et al. May 1989 A
4832008 Gilman May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4848364 Bosman Jul 1989 A
4863449 Therriault et al. Sep 1989 A
4871611 LeBel Oct 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4919654 Kalt Apr 1990 A
4930997 Bennett Jun 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4961493 Kaihatsu Oct 1990 A
4969880 Zamierowski Nov 1990 A
4981474 Bopp et al. Jan 1991 A
4985019 Michelson Jan 1991 A
4995382 Lang et al. Feb 1991 A
4996128 Aldecoa et al. Feb 1991 A
5010883 Rawlings et al. Apr 1991 A
5018515 Gilman May 1991 A
5037397 Kalt et al. Aug 1991 A
5086170 Luheshi et al. Feb 1992 A
5092323 Riedel et al. Mar 1992 A
5092858 Benson et al. Mar 1992 A
5100396 Zamierowski Mar 1992 A
5112323 Winkler et al. May 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5151314 Brown Sep 1992 A
5152757 Eriksson Oct 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5180375 Feibus Jan 1993 A
5215522 Page et al. Jun 1993 A
5232453 Plass et al. Aug 1993 A
5261893 Zamierowski Nov 1993 A
5266372 Arakawa et al. Nov 1993 A
5270358 Asmus Dec 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5342329 Croquevielle Aug 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk et al. Sep 1994 A
5356386 Goldberg et al. Oct 1994 A
5358494 Svedman Oct 1994 A
5384174 Ward et al. Jan 1995 A
5387207 Dyer et al. Feb 1995 A
5419769 Devlin et al. May 1995 A
5423778 Eriksson et al. Jun 1995 A
5429590 Saito et al. Jul 1995 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5445604 Lang Aug 1995 A
5447492 Cartmell et al. Sep 1995 A
5501212 Psaros Mar 1996 A
5512041 Bogart Apr 1996 A
5522808 Skalla Jun 1996 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5549585 Maher et al. Aug 1996 A
5556375 Ewall Sep 1996 A
5585178 Calhoun et al. Dec 1996 A
5599292 Yoon Feb 1997 A
5607388 Ewall Mar 1997 A
5634893 Rishton Jun 1997 A
5636643 Argenta et al. Jun 1997 A
5641506 Talke et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5653224 Johnson Aug 1997 A
5678564 Lawrence et al. Oct 1997 A
5710233 Meckel et al. Jan 1998 A
5714225 Hansen et al. Feb 1998 A
5736470 Schneberger et al. Apr 1998 A
5776119 Bilbo et al. Jul 1998 A
5807295 Hutcheon et al. Sep 1998 A
5919476 Fischer et al. Jul 1999 A
5941863 Guidotti et al. Aug 1999 A
5981822 Addison Nov 1999 A
6071267 Zamierowski Jun 2000 A
6086995 Smith Jul 2000 A
6135116 Vogel et al. Oct 2000 A
6174306 Fleischmann Jan 2001 B1
6191335 Robinson Feb 2001 B1
6241747 Ruff Jun 2001 B1
6262329 Brunsveld et al. Jul 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6495229 Carte et al. Dec 2002 B1
6548727 Swenson Apr 2003 B1
6553998 Heaton et al. Apr 2003 B2
6566575 Stickels et al. May 2003 B1
6566577 Addison et al. May 2003 B1
6626891 Ohmstede Sep 2003 B2
6627215 Dale et al. Sep 2003 B1
6648862 Watson Nov 2003 B2
6680113 Lucast et al. Jan 2004 B1
6685681 Lockwood et al. Feb 2004 B2
6693180 Lee et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6787682 Gilman Sep 2004 B2
6814079 Heaton et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7070584 Johnson et al. Jul 2006 B2
7154017 Sigurjonsson et al. Dec 2006 B2
7402721 Sigurjonsson et al. Jul 2008 B2
7569742 Haggstrom et al. Aug 2009 B2
7645269 Zamierowski Jan 2010 B2
8298197 Eriksson et al. Oct 2012 B2
8529532 Pinto et al. Sep 2013 B2
8632523 Eriksson et al. Jan 2014 B2
8764732 Hartwell Jul 2014 B2
9192444 Locke et al. Nov 2015 B2
20010030304 Kohda et al. Oct 2001 A1
20010051178 Blatchford et al. Dec 2001 A1
20020009568 Bries et al. Jan 2002 A1
20020016346 Brandt et al. Feb 2002 A1
20020065494 Lockwood et al. May 2002 A1
20020077661 Saadat Jun 2002 A1
20020115951 Norstrem et al. Aug 2002 A1
20020119292 Venkatasanthanam et al. Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020130064 Adams et al. Sep 2002 A1
20020143286 Tumey Oct 2002 A1
20020150270 Werner Oct 2002 A1
20020150720 Howard et al. Oct 2002 A1
20020161346 Lockwood et al. Oct 2002 A1
20020164346 Nicolette Nov 2002 A1
20020183702 Henley et al. Dec 2002 A1
20020198504 Risk et al. Dec 2002 A1
20030014022 Lockwood et al. Jan 2003 A1
20030109855 Solem et al. Jun 2003 A1
20030158577 Ginn et al. Aug 2003 A1
20030212357 Pace Nov 2003 A1
20030225347 Argenta et al. Dec 2003 A1
20030225355 Butler Dec 2003 A1
20040002676 Siegwart et al. Jan 2004 A1
20040030304 Hunt et al. Feb 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040077984 Worthley Apr 2004 A1
20040099268 Smith et al. May 2004 A1
20040118401 Smith et al. Jun 2004 A1
20040127836 Sigurjonsson et al. Jul 2004 A1
20040127862 Bubb et al. Jul 2004 A1
20040133143 Burton et al. Jul 2004 A1
20040186239 Qin et al. Sep 2004 A1
20040219337 Langley et al. Nov 2004 A1
20040230179 Shehada Nov 2004 A1
20050034731 Rousseau et al. Feb 2005 A1
20050054998 Poccia et al. Mar 2005 A1
20050059918 Sigurjonsson et al. Mar 2005 A1
20050065484 Watson Mar 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050101940 Radl et al. May 2005 A1
20050113732 Lawry May 2005 A1
20050124925 Scherpenborg Jun 2005 A1
20050131327 Lockwood et al. Jun 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20050143694 Schmidt et al. Jun 2005 A1
20050159695 Cullen et al. Jul 2005 A1
20050161042 Fudge et al. Jul 2005 A1
20050163978 Strobech et al. Jul 2005 A1
20050214376 Faure et al. Sep 2005 A1
20050233072 Stephan et al. Oct 2005 A1
20050256437 Silcock et al. Nov 2005 A1
20050261642 Weston Nov 2005 A1
20050261643 Bybordi et al. Nov 2005 A1
20050277860 Jensen Dec 2005 A1
20060079852 Bubb et al. Apr 2006 A1
20060083776 Bott et al. Apr 2006 A1
20060154546 Murphy et al. Jul 2006 A1
20060241542 Gudnason et al. Oct 2006 A1
20060271020 Huang et al. Nov 2006 A1
20070027414 Hoffman et al. Feb 2007 A1
20070078366 Haggstrom et al. Apr 2007 A1
20070185426 Ambrosio et al. Aug 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070265585 Joshi et al. Nov 2007 A1
20070265586 Joshi et al. Nov 2007 A1
20080090085 Kawate et al. Apr 2008 A1
20080119802 Riesinger May 2008 A1
20080149104 Eifler Jun 2008 A1
20080195017 Robinson et al. Aug 2008 A1
20080225663 Smith et al. Sep 2008 A1
20080243044 Hunt et al. Oct 2008 A1
20080269657 Brenneman et al. Oct 2008 A1
20080271804 Biggie et al. Nov 2008 A1
20090025724 Herron, Jr. Jan 2009 A1
20090088719 Driskell Apr 2009 A1
20090093779 Riesinger Apr 2009 A1
20090124988 Coulthard May 2009 A1
20090177172 Wilkes Jul 2009 A1
20090216204 Bhavaraju et al. Aug 2009 A1
20090227969 Jaeb et al. Sep 2009 A1
20090264807 Haggstrom et al. Oct 2009 A1
20090292264 Hudspeth et al. Nov 2009 A1
20090312662 Colman et al. Dec 2009 A1
20090326488 Budig et al. Dec 2009 A1
20100063467 Addison et al. Mar 2010 A1
20100106106 Heaton et al. Apr 2010 A1
20100106118 Heaton et al. Apr 2010 A1
20100125259 Olson May 2010 A1
20100159192 Cotton Jun 2010 A1
20100185163 Heagle Jul 2010 A1
20100226824 Ophir et al. Sep 2010 A1
20100262090 Riesinger Oct 2010 A1
20100267302 Kantner et al. Oct 2010 A1
20100305490 Coulthard et al. Dec 2010 A1
20100305524 Vess et al. Dec 2010 A1
20100324516 Braga et al. Dec 2010 A1
20110046585 Weston Feb 2011 A1
20110112458 Holm et al. May 2011 A1
20110137271 Andresen et al. Jun 2011 A1
20110160686 Ueda Jun 2011 A1
20110171480 Mori et al. Jul 2011 A1
20110172617 Riesinger Jul 2011 A1
20110224631 Simmons et al. Sep 2011 A1
20110224634 Locke Sep 2011 A1
20110229688 Cotton Sep 2011 A1
20110244010 Doshi Oct 2011 A1
20110257617 Franklin Oct 2011 A1
20120016322 Coulthard et al. Jan 2012 A1
20120123359 Reed May 2012 A1
20120143157 Riesinger Jun 2012 A1
20120258271 Maughan Oct 2012 A1
20130030394 Locke et al. Jan 2013 A1
20130066285 Locke et al. Mar 2013 A1
20130096518 Hall et al. Apr 2013 A1
20130152945 Locke et al. Jun 2013 A1
20140012213 Locke Jan 2014 A1
20140039423 Riesinger Feb 2014 A1
20140039424 Locke Feb 2014 A1
20140058309 Addison Feb 2014 A1
20140155849 Heaton et al. Jun 2014 A1
20140171851 Addison Jun 2014 A1
20140309574 Cotton Oct 2014 A1
20140350494 Hartwell et al. Nov 2014 A1
20150030848 Goubard Jan 2015 A1
20150119830 Luckemeyer et al. Apr 2015 A1
20150190286 Allen et al. Jul 2015 A1
20160067107 Cotton Mar 2016 A1
Foreign Referenced Citations (130)
Number Date Country
550575 Mar 1986 AU
745271 Mar 2002 AU
755496 Dec 2002 AU
2009200608 Oct 2009 AU
2005436 Jun 1990 CA
87101823 Aug 1988 CN
26 40 413 Mar 1978 DE
43 06 478 Sep 1994 DE
29 504 378 Sep 1995 DE
202004018245 Jul 2005 DE
0097517 Jan 1984 EP
0100148 Feb 1984 EP
0117632 Sep 1984 EP
0161865 Nov 1985 EP
0251810 Jan 1988 EP
0275353 Jul 1988 EP
0358302 Mar 1990 EP
0538917 Apr 1993 EP
0630629 Dec 1994 EP
0659390 Jun 1995 EP
0633758 Oct 1996 EP
1002846 May 2000 EP
1018967 Jul 2000 EP
2578193 Apr 2013 EP
692578 Jun 1953 GB
1386800 Mar 1975 GB
2 195 255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2 329 127 Mar 1999 GB
2 333 965 Aug 1999 GB
2377939 Jan 2003 GB
2392836 Mar 2004 GB
2393655 Apr 2004 GB
2425487 Nov 2006 GB
2452720 Mar 2009 GB
2496310 May 2013 GB
1961003393 Feb 1961 JP
S62139523 Sep 1987 JP
S62-275456 Nov 1987 JP
08-336555 Dec 1996 JP
2007254515 Oct 2007 JP
2008080137 Apr 2008 JP
4129536 Aug 2008 JP
2015501712 Jan 2015 JP
71559 Apr 2002 SG
8002182 Oct 1980 WO
8704626 Aug 1987 WO
8707164 Dec 1987 WO
90010424 Sep 1990 WO
93009727 May 1993 WO
WO-9313813 Jul 1993 WO
WO-9319709 Oct 1993 WO
94020041 Sep 1994 WO
WO-9515135 Jun 1995 WO
9605873 Feb 1996 WO
9622753 Aug 1996 WO
9718007 May 1997 WO
9913793 Mar 1999 WO
9965542 Dec 1999 WO
0136188 May 2001 WO
0160296 Aug 2001 WO
0168021 Sep 2001 WO
0185248 Nov 2001 WO
WO-0220067 Mar 2002 WO
0243743 Jun 2002 WO
02062403 Aug 2002 WO
03-018098 Mar 2003 WO
WO-03043553 May 2003 WO
03045294 Jun 2003 WO
03045492 Jun 2003 WO
03053484 Jul 2003 WO
2004024197 Mar 2004 WO
2004037334 May 2004 WO
WO-2004060359 Jul 2004 WO
WO-2004060413 Jul 2004 WO
2004112852 Dec 2004 WO
2005002483 Jan 2005 WO
2005062896 Jul 2005 WO
2005105176 Nov 2005 WO
2005123170 Dec 2005 WO
2007022097 Feb 2007 WO
2007030601 Mar 2007 WO
2007070269 Jun 2007 WO
2007085396 Aug 2007 WO
2007087811 Aug 2007 WO
2007113597 Oct 2007 WO
WO-2007113597 Oct 2007 WO
2007133618 Nov 2007 WO
2008041926 Apr 2008 WO
2008054312 May 2008 WO
WO-2008062176 May 2008 WO
2008082444 Jul 2008 WO
2008100440 Aug 2008 WO
2008104609 Sep 2008 WO
2008131895 Nov 2008 WO
2009002260 Dec 2008 WO
2008149107 Dec 2008 WO
2009066105 May 2009 WO
2009066106 May 2009 WO
WO-2009067062 May 2009 WO
2009081134 Jul 2009 WO
2009089016 Jul 2009 WO
2009124100 Oct 2009 WO
2009126103 Oct 2009 WO
2010032728 Mar 2010 WO
2010056977 May 2010 WO
WO-2010061228 Jun 2010 WO
WO-2010122665 Oct 2010 WO
2010129299 Nov 2010 WO
2011008497 Jan 2011 WO
2011049562 Apr 2011 WO
2011043786 Apr 2011 WO
2011115908 Sep 2011 WO
2011121127 Oct 2011 WO
2011162862 Dec 2011 WO
2012112204 Aug 2012 WO
2012104584 Aug 2012 WO
2012140378 Oct 2012 WO
2012143665 Oct 2012 WO
WO-2012140378 Oct 2012 WO
2013009239 Jan 2013 WO
2013090810 Jun 2013 WO
2014039557 Mar 2014 WO
2014113253 Jul 2014 WO
2014140608 Sep 2014 WO
2014143488 Sep 2014 WO
2015065615 May 2015 WO
2015130471 Sep 2015 WO
Non-Patent Literature Citations (92)
Entry
Louis C. Argenta, MD and Michael J. Morykwas, PhD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery.
Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.
James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA.
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 198, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK.
S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487.
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639.
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80.
International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995.
PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999.
PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999.
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997.
PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997.
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp: 1-5.
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof.
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof.
Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof.
Davydov, Yu.A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct. 1988, pp: 48-52, and 8 page English translation thereof.
Davydov, Yu.A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24.
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2.
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534.
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81.
Arnljots, Bjöm et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213.
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221.
Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (copy and certified translation).
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246.
G. {hacek over (Z)}ivadinovi?, V. ?uki?, {hacek over (Z)}. Maksimovi?, ?. Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (copy and certified translation).
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585.
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (copy and certified translation).
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370.
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513.
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I).
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549.
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211.
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”).
V.A. Kuznetsov & N.A. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”).
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”).
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007.
M. Waring et al., “Cell attachment to adhesive dressing: qualitative and quantitative analysis”, Wounds, UK, (2008), vol. 4, No. 3, pp. 35-47.
R. White, “Evidence for atraumatic soft silicone wound dressing use”. Wound, UK (2005), vol. 3, pp. 104-108, Mepilex Border docs, (2001).
European Search Report for corresponding application 17183683.6, dated Sep. 18, 2017.
European Search Report for corresponding application 17164033.7, dated Oct. 13, 2017.
Extended European Search Report for corresponding application 17191970.7, dated Oct. 26, 2017.
International Search Report and Written Opinion for PCT/GB2008/003075 dated Mar. 11, 2010.
International Search Report and Written Opinion for PCT/GB2008/004216 dated Jul. 2, 2009.
International Search Report and Written Opinion for PCT/GB2012/000099 dated May 2, 2012.
EP Examination Report for corresponding application 12705381.7, dated May 22, 2014.
International Search Report and Written Opinion for PCT/US2012/069893 dated Apr. 8, 2013.
International Search Report and Written Opinion for PCT/US2013/070070 dated Jan. 29, 2014.
International Search Report and Written Opinion for PCT/US2014/016320 dated Apr. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/056566 dated Dec. 5, 2014.
International Search Report and Written Opinion for PCT/US2014/056508 dated Dec. 9, 2014.
International Search Report and Written Opinion for PCT/US2014/056524 dated Dec. 11, 2014.
International Search Report and Written Opinion for PCT/US2014/056594 dated Dec. 2, 2014.
International Search Report and Written opinion dated Dec. 15, 2009; PCT Internation Application No. PCT/US2009/036222.
Response filed Oct. 20, 2011 for U.S. Appl. No. 12/398,904.
Interview Summary dated Oct. 27, 2011 for U.S. Appl. No. 12/398,904.
Non-Final Office Action dated dated Jul. 20, 2011 for U.S. Appl. No. 12/398,904.
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medican Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”).
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”).
NDP 1000 Negative Pressure Wound Terapy System, Kalypto Medical, pp. 1-4.
Examination report for AU2009221772 dated Apr. 4, 2013.
Response filed Oct. 21, 2011 for U.S. Appl. No. 12/398,891.
Interview Summary dated Oct. 27, 2011 for U.S. Appl. No. 12/398,891.
Restriction Requirement dated Jun. 13, 2011 for U.S. Appl. No. 12/398,891.
Response filed Jun. 24, 2011 for U.S. Appl. No. 12/398,891.
Non-Final Office Action dated Jul. 21, 2011 for U.S. Appl. No. 12/398,891.
International Search Report and Written Opinion dated Oct. 19, 2010; PCT International Application No. PCT/US2009/036217.
NPD 1000 Negative Pressure Would Therapy System, Kalypto Medical, pp. 1-4.
Non-Final Rejection for U.S. Appl. No. 12/398,904 dated Mar. 14, 2012.
Response to Non-Final Rejection for U.S. Appl. No. 12/398,904, filed Jun. 4, 2012.
International Search Report and Written Opinion for PCT/US2014/061251 dated May 8, 2015.
International Search Report and Written Opinion for PCT/IB2013/060862 dated Jun. 26, 2014.
International Search Report and Written Opinion for PCT/US2015/015493 dated May 4, 2015.
European Search Report for corresponding Application No. 15194949.2.
European Examination Report dated Jun. 29, 2016, corresponding to EP Application No. 16173614.5.
European Search Report for corresponding EPSN 15157408.4 published on Sep. 30, 2015.
International Search Report and Written Opinion for PCT/US2015/034289 dated Aug. 21, 2015.
International Search Report and Written Opinion for PCT/US2015/065135 dated Apr. 4, 2016.
International Search Report and Written Opinion for PCT/GB2012/050822 dated Aug. 8, 2012.
International Search Report and Written Opinion for PCT/US2015/029037 dated Sep. 4, 2015.
International Search Report and Written Opinion date dated Jun. 1, 2011 for PCT International Application No. PCT/US2011/028344.
European Search Report for EP 11714148.1, dated May 2, 2014.
European Search Report for corresponding Application No. 15192606.0 dated Feb. 24, 2016.
International Search Report and Written Opinion for corresponding PCT/US2014/048081 dated Nov. 14, 2014.
International Search Report and Written Opinion for corresponding PCT/US2014/010704 dated Mar. 25, 2014.
International Search Report and Written Opinion for corresponding PCT application PCT/US2016/051768 dated Dec. 15, 2016.
European Search Report for corresponding EP Application 171572787 dated Jun. 6, 2017.
International Search Report and Written Opinion for corresponding application PCT/US2016/031397, dated Aug. 8, 2016.
European Search Report for corresponding application 17167872.5, dated Aug. 14, 2017.
Related Publications (1)
Number Date Country
20180021180 A1 Jan 2018 US
Continuations (1)
Number Date Country
Parent 14653760 US
Child 15659486 US